Early in my career in drug development I worked on clinical trials for Alzheimer’s Disease. The drugs were mildly efficacious (that means they work) but they had nasty side effect profiles. When I heard the news this week about the drugs being pulled from the market, I began to wonder when we would take some of the less invasive options seriously.
